🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

At #ASCO25 Toni Choueiri, MD presents the first data from the ARC-20 study looking at casdatifan (HIF2 inhibitor) + cabozantinib (VEGF TKI) in metastatic clear cell #KidneyCancer. Combo showed encouraging efficacy and next up is a planned phase 3 trial. Dana-Farber Lank Center for Genitourinary Oncology

“It is incredibly important for us, as a field, to be thinking about how our diet and lifestyle impacts not just our risk of developing [colon] cancer, but then how people fare after it,” Dana-Farber’s Sara Khosrowjerdi Char, MD told CNN. Read more about promising new research presented at

Adding immune checkpoint inhibitor to standard chemotherapy regimen improves outcomes in stage 3 #colon cancer that is deficient in DNA mismatch repair. ATOMIC Trial results today at #ASCO25. Dana-Farber's Jeff Meyerhardt, MD, MPH, is senior author. Press release here:

When CHECKMATE 214 launched 9 years ago, 5-year survival in metastatic #KidneyCancer was just 5%. Now, final 9-year data at #ASCO25 shows >30% of patients still alive. The trial made nivolumab + ipilimumab standard first-line care. Toni Choueiri, MD explains. Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber

Colon cancer and diet research at #ASCO25: A new study shows that consuming an anti-inflammatory diet could extend overall survival after treatment for stage 3 #colon cancer. Dana-Farber's Sara Khosrowjerdi Char, MD presents the findings and provides more details in this video. Senior author

Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows. Read more about new research from Dana-Farber’s Sara Tolaney, presented at #ASCO25, in STAT: statnews.com/2025/05/31/tro…

Now at ASCO, Dana-Farber’s Sara Tolaney, MD, shares results of DESTINY-09: TdxD + pertuzumab nearly doubled PFS in pts with newly dx HER2+ mbc. Findings could be new standard of care for these pts for the first time in a decade. Dana-Farber’s Breast Oncology Center #ASCO25 ➡️

Psychosocial intervention for adolescents and young adults with advanced cancer improves resilience immediately and quality of life over time. Abby Rosenberg, MD, MS, MA of Dana-Farber/Boston Children's presents findings of PRISM-AC at #ASCO25.

The near-doubling of progression-free survival suggests combo of trastuzumab deruxtecan + pertuzumab may be a new standard of care for HER2+ metastatic #BreastCancer, says Dana-Farber's Sara Tolaney, MD, MPH, presenting DESTINY-Breast09 at #ASCO25. Sara Tolaney Dana-Farber’s Breast Oncology Center

Watch 7News Boston WHDH at the new Ning Zhao & Ge Li Simulation Center, where Dana-Farber nurses are learning life-saving skills in one of the only simulation centers in the U.S. dedicated to oncology: bit.ly/43YP6la

Today at #ASCO25: Glenn J. Hanna, M.D. of Dana-Farber presents phase 2 data suggesting circulating HPV DNA can be a biomarker before & during treatment for HPV-positive oropharyngeal cancer to guide treatment intensity w/o compromising PFS survival in higher-risk pts.

“These data have the potential to establish a new standard of care for the first-line treatment of metastatic, HER2-positive breast cancer,” said Sara Tolaney, Chief of the Division of Breast Oncology Dana-Farber. Read more about research presented at #ASCO25 in STAT:

Jeffrey Meyerhardt, co-director of the Colon and Rectal Care Center Dana-Farber, talked with NBC News about a new study, presented at #ASCO25, that suggests exercise may benefit colon cancer patients as much as some drugs: nbcnews.com/health/cancer/…

At #ASCO25: A cell-free, DNA-guided strategy in advanced #NSCLC helped personalize first-line treatment—identifying patients who may delay or avoid chemo without compromising outcomes. Presented by Julia Rotow MD Dana-Farber

An anti-inflammatory diet may help colon cancer patients live longer, study says. Dana-Farber’s Sara Khosrowjerdi Char, MD and Kimmie Ng, MD, MPH talked with NBC News about their research on diet and #coloncancer presented at #ASCO25: bit.ly/451IZOb

First study of triplet combination of letrozole, abemaciclib, and metformin in any cancer type reported at #ASCO25. Panos Konstantinopoulos, MD, PhD, of Dana-Farber says the results of a phase 2 study in ER+ recurrent #endometrial cancer were encouraging.

Step inside Dana-Farber’s new Ning Zhao & Ge Li Simulation Center — where nurses and care teams train for real-world cancer care scenarios in a safe, high-tech environment. 🔗 Watch the video here. #SimulationTraining #PatientSafety #MedicalInnovation

Congratulations to Dana-Farber’s Miriam Agyakomah Osei, MD for being selected by ASH to receive the 2025 ASH Hematology Inclusion Pathway (HIP) Fellow Award (under the mentorship of Drs. Lachelle Dawn and Coleman Lindsley). This is part of ASH’s investment in research and

.Dana-Farber’s Tim Rebbeck joins Dan Rea on Dan Rea to discuss the importance of sunscreen in cancer prevention and dispel increasingly common myths about its use. Watch at the 23:35 mark: bit.ly/3HqThh7

“If you want to be on the cutting-edge of cancer care, this is the place to be, certainly in our region, if not nationally,” said Jeanine Rundquist, DNP, RN, NEA-BC, executive director of Dana-Farber's Center for Clinical and Professional Development.